These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 1397061)

  • 1. Molecular modelling of asperlicin derived cholecystokinin A receptor antagonists.
    Van der Bent A; Ter Laak AM; IJzerman AP; Soudijn W
    Eur J Pharmacol; 1992 Aug; 226(4):327-34. PubMed ID: 1397061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. His381 of the rat CCKB receptor is essential for CCKB versus CCKA receptor antagonist selectivity.
    Jagerschmidt A; Guillaume-Rousselet N; Vikland ML; Goudreau N; Maigret B; Roques BP
    Eur J Pharmacol; 1996 Jan; 296(1):97-106. PubMed ID: 8720482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hybrid cholecystokinin-A antagonists based on molecular modeling of lorglumide and L-364,718.
    van der Bent A; Blommaert AG; Melman CT; IJzerman AP; van Wijngaarden I; Soudijn W
    J Med Chem; 1992 Mar; 35(6):1042-9. PubMed ID: 1552499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined dose-ratio analysis of cholecystokinin receptor antagonists, devazepide, lorglumide and loxiglumide in the guinea-pig gall bladder.
    Bishop LA; Gerskowitch VP; Hull RA; Shankley NP; Black JW
    Br J Pharmacol; 1992 May; 106(1):61-6. PubMed ID: 1504732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular design of potent specific antagonists for the gastrin and cholecystokinin receptors.
    Evans BE
    Z Gastroenterol Verh; 1991 Mar; 26():269-71. PubMed ID: 1714170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and evaluation of asperlicin analogues as non-peptidal cholecystokinin-antagonists.
    Lattmann E; Billington DC; Poyner DR; Howitt SB; Offel M
    Drug Des Discov; 2001; 17(3):219-30. PubMed ID: 11469752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of type A and type B CCK receptor binding sites in rat vagus nerve.
    Corp ES; McQuade J; Moran TH; Smith GP
    Brain Res; 1993 Sep; 623(1):161-6. PubMed ID: 8221086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of CCK receptors in a novel smooth muscle preparation from the guinea-pig stomach by use of the selective antagonists CI-988, L-365,260 and devazepide.
    Boyle SJ; Tang KW; Woodruff GN; McKnight AT
    Br J Pharmacol; 1993 Aug; 109(4):913-7. PubMed ID: 8401944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in motor activity and forebrain [propionyl-3H]propionylated-CCK-8 binding in mice after repeated administration of drugs affecting cholecystokinin receptors.
    Vasar E; Stephenson JD; Meldrum BS
    Eur J Pharmacol; 1991 Sep; 202(3):385-90. PubMed ID: 1748160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutational analysis of the putative devazepide binding site of the CCK(A) receptor.
    Smeets RL; IJzerman AP; Hermsen HP; Ophorst OJ; Van Emst-de Vries SE; De Pont JJ; Willems PH
    Eur J Pharmacol; 1997 Apr; 325(1):93-9. PubMed ID: 9151944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hybrid cholecystokinin (CCK) antagonists: new implications in the design and modification of CCK antagonists.
    Kerwin JF; Nadzan AM; Kopecka H; Lin CW; Miller T; Witte D; Burt S
    J Med Chem; 1989 Apr; 32(4):739-42. PubMed ID: 2704023
    [No Abstract]   [Full Text] [Related]  

  • 12. Intermolecular interactions between peptidic and nonpeptidic agonists and the third extracellular loop of the cholecystokinin 1 receptor.
    Giragossian C; Sugg EE; Szewczyk JR; Mierke DF
    J Med Chem; 2003 Jul; 46(16):3476-82. PubMed ID: 12877585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of [3H](+/-)L-364,718 binding to solubilized cholecystokinin (CCK) receptors of rat pancreas.
    Chang RS; Lotti VJ; Chen TB
    Biochem Pharmacol; 1987 May; 36(10):1709-14. PubMed ID: 3593394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the binding of [3H]-(+/-)-L-364,718: a new potent, nonpeptide cholecystokinin antagonist radioligand selective for peripheral receptors.
    Chang RS; Lotti VJ; Chen TB; Kunkel KA
    Mol Pharmacol; 1986 Sep; 30(3):212-7. PubMed ID: 3018478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic potential of cholecystokinin receptor antagonists in CNS disorders.
    Schiantarelli P
    Pharmacol Res; 1993; 28(1):1-9. PubMed ID: 8234141
    [No Abstract]   [Full Text] [Related]  

  • 16. 5-(Piperidin-2-yl)- and 5-(homopiperidin-2-yl)-1,4-benzodiazepines: high-affinity, basic ligands for the cholecystokinin-B receptor.
    Castro JL; Broughton HB; Russell MG; Rathbone D; Watt AP; Ball RG; Chapman KL; Patel S; Smith AJ; Marshall GR; Matassa VG
    J Med Chem; 1997 Aug; 40(16):2491-501. PubMed ID: 9258356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholecystokinin satiety involves CCKA receptors perfused by the superior pancreaticoduodenal artery.
    Cox JE
    Am J Physiol; 1998 May; 274(5):R1390-6. PubMed ID: 9612407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypolocomotion induced by peripheral or central injection of CCK in the mouse is blocked by the CCKA receptor antagonist devazepide but not by the CCKB receptor antagonist L-365,260.
    O'Neill MF; Dourish CT; Iversen SD
    Eur J Pharmacol; 1991 Feb; 193(2):203-8. PubMed ID: 2050197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiation of central cholecystokinin receptor binding sites using the non-peptide antagonists MK-329 and L-365,260.
    Hill DR; Woodruff GN
    Brain Res; 1990 Sep; 526(2):276-83. PubMed ID: 2257485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of receptor desensitization to analyse CCKA and CCKB/gastrin receptors coupled to contraction in guinea-pig stomach muscle.
    Bishop LA; Gerskowitch VP; Hull RA; Shankley NP; Black JW
    Br J Pharmacol; 1995 Jan; 114(2):339-48. PubMed ID: 7881733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.